Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers musculoskeletal solutions, including spine products, such as traditional fusion implants, and treatment options for motion preservation technologies, and interventional solutions to treat vertebral compression fractures; orthopedic trauma solutions, which includes fracture plating, intramedullary nailing, and regenerative biologic products; hip and knee joint solutions, including modular hip stems and acetabular cups for total hip arthroplasty, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants; and neuromonitoring services, which provides onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also offers enabling technologies, such as imaging, navigation, and robotics (INR) solutions for assisted surgery, which includes the ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures with screw and interbody spacer placement applications; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative, image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cell, tissue, and cellular and tissue-based products. The company sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Globus Medical Inc. Class A

In a report released on January 7, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Globus Medical, with a price target of $100.00. ...

RBC Capital Reaffirms Their Buy Rating on Globus Medical (GMED)

Jefferies analyst Matthew Taylor reiterated a Buy rating on Globus Medical today and set a price target of $115.00. Taylor covers the Healthcare se...

Jefferies Sticks to Its Buy Rating for Globus Medical (GMED)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD – Research Report) and Gl...

Analysts’ Top Healthcare Picks: Revolution Medicines (RVMD), Globus Medical (GMED)

Barclays analyst Matt Miksic maintained a Buy rating on Globus Medical today and set a price target of $118.00. Miksic covers the Healthcare sector...

Barclays Keeps Their Buy Rating on Globus Medical (GMED)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Globus Medical (GMED – Research Report) and Verrica Pharmaceutica...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GMED	$89.70	-1.08%	858.00K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GMED	$89.70	-1.1%	858.00K
3
4
5
6

GMED

GMED

No Data Available

Get Globus Medical Inc. Class A Data in Excel

Get Globus Medical Inc. Class A Data in Excel